Results 11 to 20 of about 2,650 (185)

Conbercept treatment for heart-shaped vascular intertwined nets in macular neovascularization:anti-VEGF drug therapy strategy based on vascular geometry diagnosed by OCTA [PDF]

Clinical Case Reports, Volume 13, Issue 10, October 2025.
Macular neovascularization (MNV), a hallmark of several retinal disorders including ocular trauma and wet age-related macular degeneration, remains a major cause of vision impairment due to the proliferation of abnormal, fragile blood vessels.
Cai, Minqing, Ou, Shangkun, Shi, Feiping, Wu, Yiming   +3 more
core   +2 more sources

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. [PDF]

, 2023
Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related
Blum, Claudine A, Copt, René-Pierre, Eandi, Chiara M, Garweg, Justus G, Hatz, Katja, Prünte, Christian F, Seelig, Eleonora, Somfai, Gábor M   +7 more
core   +4 more sources

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2022
Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous.
Junlan Chuan, Junlan Chuan, Lianqiao Liu, Lianqiao Liu, Yumei Feng, Mengdan Wang, Mengdan Wang, Gang Li, Gang Li, Gang Li, Qin Lv   +10 more
doaj   +1 more source

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review. [PDF]

, 2023
Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine.
Garweg, Justus G., Keiper, Judith, Pfister, Isabel B, Schild, Christin   +3 more
core   +1 more source

A post hoc Evaluation of Data from the HAWK and HARRIER Trials [PDF]

, 2022
Funding Information: Development of this publication was funded by Novartis Pharma AG including medical writing and editorial assistance. The sponsor participated in data analysis, interpretation of the data, and review of the manuscript.
B, Guruprasad B., Chhablani, Jay, Clemens, Andreas, Flores, Rita, Gedif, Kinfemichael, Khanani, Arshad M., Liu, Xiaoxi, Mulyukov, Zufar, Querques, Giuseppe, Singer, Michael, Wolf, Armin   +10 more
core   +1 more source

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report

Case Reports in Ophthalmology, 2022
This report describes a case of choroidal effusion after intravitreal brolucizumab injection for wet age-related macular degeneration (AMD). A 71-year-old Korean man with a history of wet AMD visited our clinic.
Ha Eun Sim, Jae Suk Kim, Je Hyung Hwang
doaj   +1 more source

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2023
Background The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD).
Joseph M. Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P. Hull, Shawn A. Lewis, David G. Miller, Michael A. Novak, Scott D. Pendergast, Hang Pham, Sean M. Platt, Llewelyn J. Rao, Jerome P. Schartman, Lawrence J. Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher   +18 more
doaj   +1 more source

Brolucizumab [PDF]

Reactions Weekly, 2020
Wie Aflibercept und Ranibizumab hemmt Brolucizumab den «Vascular Endothelial Growth Factor» (VEGF) und kann zur intravitrealen Behandlung der exsudativen (neovaskulären) altersbedingten Makuladegeneration eingesetzt werden. VEGF-Hemmer können zu entzündlichen Augenkomplikationen führen.
  +5 more sources

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study

Indian Journal of Ophthalmology, 2023
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers
Debdulal Chakraborty, Soumen Mondal, Sabyasachi Sengupta, Zahir Abbas, Khushboo Chandra, Subhendu Boral, Aniruddha Maiti, Sangeeta Roy, Angshuman Mukherjee, Arnab Das, Somnath Chakraborty, Pinaki Nag   +11 more
doaj   +1 more source

Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy [PDF]

, 2023
Purpose: To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy.
Affatato M., Bonfiglio V., Carnevali A., Carosielli M., Chiosi F., Chronopoulos A., Costagliola C., Cucciniello P., D'albenzio A., Dell'omo R., Fallico M., Filippelli M., Manzi G., Pirozzi E., Randazzo G., Rapino G., Rinaldi M., Rosa N., Scorcia V., Vadala' M., Vaiano A., Venturi F.   +21 more
core   +1 more source